Skip to main content

ConcertAI Introduces Cadence Suite, Delivering Industry Leading Visibility and Predictive Insights into the Patient’s Journey for Commercial Teams

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

AI-native platform connects specialty pharmacy and claims data to detect access barriers and reduce therapy drop-offs

ConcertAI®, a leading real-world evidence and AI SaaS technology company, today introduced Cadence Suite, an AI-native suite of applications designed for pharmaceutical commercial and field teams to identify and resolve patient access barriers before they lead to therapy disruption. By providing near real-time visibility across the brand and patient journey, Cadence Suite helps teams intervene sooner to support better patient outcomes and improved business performance.

When patients experience friction in their care journey, health outcomes suffer and therapy drop-off rates increase. Cadence Suite helps prevent these pain points by unifying specialty pharmacy data, claims data and social determinants of health into a connected view that converts complex information into actionable intelligence. This connected view empowers teams to detect friction points earlier, reduce delays, and improve therapy adherence.

"Every day a patient waits for treatment can impact both their health and therapy providers’ business performance,” said Eron Kelly, Chief Executive Officer of ConcertAI. “Leveraging our background in orchestrating highly complex health data, we created an AI-powered solution that pinpoints explicit gaps that hinder treatment adherence – ultimately helping patients access the medications they need."

The suite is powered by CARA™, ConcertAI’s proprietary agentic AI platform. It aggregates commercial data and applies automated, real-time quality checks to reduce data errors by up to 25% and allows teams to work from a single source of truth. Cadence Suite can be fully implemented in as little as 30 days, helping teams quickly operationalize proactive intervention.

"ConcertAI has already made a meaningful impact for our team by providing easier access to insights," said Greg Rechtenbach, Director of Reimbursement at Jazz Pharmaceuticals. "The ability to quickly view, save, and share standardized reports keeps our field team aligned, and the AI-powered predictive alerts help us proactively address patient access issues. The curated data provided by ConcertAI is more reliable than what we were using before, ensuring we are working from a solid foundation."

Cadence Suite is designed to unite key stakeholders across payers, pharmacies, and regions through AI-powered benchmarking dashboards that provide daily visibility into critical measures like fill rate, time-to-fill, and persistency, with automated alerts that flag emerging risk. For field reimbursement teams, secure case management tools and intelligent workflows support triage and follow-through on “stuck” patients. For Trade and Distribution teams, inventory management capabilities provide predictive alerts for supply risks and potential stockouts to help prevent missed doses caused by distribution issues.

Interested audiences can see Cadence Suite live at Asembia’s AXS26 Summit in booth #1628, from April 26 to April 30, 2026, in Las Vegas.

About ConcertAI

ConcertAI provides purpose-built, enterprise artificial intelligence and real-world data solutions for life sciences and healthcare organizations, turning complex health data into actionable insights that advance research and care. Its proprietary Precision Suite SaaS solution and CARA platform deliver agentic AI capabilities designed for healthcare’s biggest challenges and are trained specifically for life sciences use cases like translational medicine, clinical development, clinical trials and commercial acceleration. Working with 75% of the top 30 life sciences organizations, more than 2,000 healthcare providers and medical societies, and a broad network of industry partners, ConcertAI has built the market’s most comprehensive clinicogenomic datasets to fuel drug development, trial acceleration, and advance clinical care. Through our data, AI technology, partnerships, and expertise, we empower oncologists and radiologists with real-time clinical insights at the point of care for better patient outcomes, and equip researchers with solutions to accelerate life-changing therapies to patients. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, and Tokyo. Learn more at concertai.com.

By providing near real-time visibility across the brand and patient journey, Cadence Suite helps teams intervene sooner to support better patient outcomes and improved business performance.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  252.54
+4.26 (1.72%)
AAPL  268.94
-4.11 (-1.51%)
AMD  279.98
+5.03 (1.83%)
BAC  54.06
+0.11 (0.20%)
GOOG  335.46
+0.06 (0.02%)
META  672.36
+1.45 (0.22%)
MSFT  424.68
+6.61 (1.58%)
NVDA  201.38
-0.68 (-0.34%)
ORCL  182.16
+4.58 (2.58%)
TSLA  391.22
-1.28 (-0.33%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.